A novel non-transgenic fly model for tauopathies

The Kuo lab at Michigan State University has received an R21 grant from the National Institute on Aging, NIH, to develop a novel non-transgenic fly model for tauopathies. This two-year exploratory project aims to create and validate an adult Drosophila model that recapitulates age-dependent neurological and behavioral deficits by orally administering recombinant hyperphosphorylated tau protein produced in the Kuo laboratory. Tauopathies neurodegenerative disorders that include Alzheimer's disease, certain forms of frontotemporal dementia, and chronic traumatic encephalopathy affect millions and currently have no cure or preventive therapies. The proposed model leverages a feeding-based approach, described by the investigators as an model, to induce tau-related pathology without genetic modification of the organism. By delivering hyperphosphorylated tau protein through the diet of adult flies, the team observes progressive, age-dependent neurological and behavioral deficits in the experimental cohort, providing a platform to study disease mechanisms in a tractable invertebrate system.

The project is exploratory and designed to test feasibility and utility of this non-transgenic paradigm for modeling tau-mediated neurodegeneration. One major goal is to elucidate underlying disease mechanisms triggered by exogenously supplied pathological tau, including how the protein interacts with neuronal systems in an adult organism and how age contributes to vulnerability. Another key aim is translational: the fly model will function as a pre-vertebrate gating assay to identify and prioritize candidate therapeutics for Alzheimer's disease and other tauopathies. By enabling rapid, cost-effective screening of compounds in a whole-organism context, the model seeks to accelerate early-stage drug discovery and provide a biologically relevant bridge between molecular assays and vertebrate preclinical testing.

The approach capitalizes on the strengths of Drosophila as a research organism short lifespan, well-characterized nervous system, and amenability to behavioral assays ”while avoiding genetic manipulation that can confound interpretation of protein-driven pathology. Feeding recombinant hyperphosphorylated tau to adult flies offers a controlled method to introduce pathological protein and observe resultant phenotypes over time. The Kuo lab's in-house production of recombinant hyperphosphorylated tau enables precise experimental control over the material delivered to flies and supports reproducible assessment of dose, timing, and behavioral outcomes.

This R21-funded effort positions the Kuo lab to contribute a novel tool to the tauopathy research community: a scalable, non-transgenic fly model that can both illuminate mechanisms of tau-mediated neurodegeneration and serve as an efficient screen to triage candidate therapeutics before moving into vertebrate models. The work aligns mechanistic investigation with applied drug discovery, addressing the urgent need for models that can help identify interventions for devastating, currently incurable neurodegenerative diseases.